CANNON EXPLORATION INCORPORATED (OTC: CNEX)
"Up 162.50% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/CNEX.php

China Shuangji Cement Corporation, through its interest in Shandong Zhaoyuan Shuangji Group, Ltd., operates in the cement industry in the People's Republic of China and internationally. It offers portland cement and other cement products, which are used in the construction of buildings, roads, and other infrastructure projects. The company, formerly known as Citisource, Inc., was founded in 1983 and is based in Kent, the People's Republic of China.

CNEX News:

May 7 - Cannon Exploration Inc. Updates Shareholders

Cannon Exploration Inc. (OTC: CNEX), a North American mining company, announced that effective May 7th, the company's website (www.cannon-exploration.com) will be live and that an Investor Relations firm has been hired to take shareholder inquires at 1-866-365-4724.

The company plans to own several advanced mining properties in North America that will rapidly combine a balanced portfolio of exploration and development projects with the mining expertise of its technical and managerial teams to ensure future growth of the company. The result is a company with the share liquidity and market capitalization to provide value to investors. "As we move forward in considering exciting growth options for the company, I hope that in the coming months you will come to share that excitement with me as well," stated CEO Neil Sarran.

The company will be updating its shareholders with further announcements within the near future with regards to company projects and developments.

IMARX THERAPEUTICS (NASD: IMRX)
"Up 154.62% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/IMRX.php

ImaRx Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for vascular disorders in the United States. Its commercialization efforts are focused on urokinase, a thrombolytic drug used for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The company sells urokinase to wholesale distributors under the Kinlytic brand name. Its research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The company's research stage programs include Targeted SonoLysis Therapy, which includes study for MRX-802 targeted microbubbles to treat vascular clots; and Targeted Drug Delivery to study the changes in the permeability of the blood-brain barrier with its proprietary MRX-809 targeted microbubbles and ultrasound. ImaRx Therapeutics, Inc. was founded in 1999 and is headquartered in Tucson, Arizona.

IMRX News:

May 7 - ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase

Microbix to Acquire Commercialized Thrombolytic and Related Assets for $17 Million

ImaRx Therapeutics, Inc. (NASD: IMRX) announced that it has signed a letter of intent in which Microbix Biosystems will acquire urokinase inventory and related assets from ImaRx for $17 million in cash. Urokinase is an FDA-approved thrombolytic, or clot-dissolving agent, indicated for the treatment of acute massive pulmonary embolism. ImaRx acquired an approximate four year inventory of the product from Abbott Laboratories and has been selling the product from inventory since 2006.

Bradford A. Zakes, President and CEO of ImaRx, stated, "The proceeds to be generated through this transaction provide ImaRx with a solid source of non- dilutive financing. We are very pleased with the terms under which we have reached agreement with Microbix on the sale of our urokinase asset. Through this transaction, ImaRx will have gained access to operating capital under favorable economic terms that will enable the company to continue the advancement of our core SonoLysis technology."

Under terms of the agreement, Microbix will acquire the urokinase product and related assets for an upfront payment of $12 million plus an additional $5 million upon achievement of an inventory stability milestone. Upon closing, Microbix will assume full responsibility for urokinase, including sales, marketing and regulatory compliance requirements. To facilitate the inventory stability milestone, Microbix will engage ImaRx in a support services agreement.

ImaRx had previously announced in January 2008 that it had signed a letter of intent to partner with Microbix in the transfer of the manufacturing process and production of a new supply of urokinase. Zakes stated, "Whereas we viewed the manufacturing partnership with Microbix under the structure of our original letter of intent as an attractive means of maintaining an ongoing supply of urokinase in the marketplace, we ultimately concluded that selling the entire asset to Microbix created an even greater value proposition for ImaRx by enabling the company to accelerate the monetization of our existing inventory and utilize the proceeds towards the advancement of our SonoLysis program."

This decision was further supported by the company's announcement in April 2008 that it had fully satisfied all of its obligations under the $15 million non-recourse promissory note to Abbott Laboratories in exchange for the payment of $5.2 million in cash and certain payables.

Mr. Zakes concluded, "SonoLysis represents the original investment thesis for the vast majority of our existing shareholders. ImaRx is recognized world wide as a leader in the development of microbubble technologies and has a proven track record in this field. We have an experienced and talented team of scientists that are passionate about this program and dedicated in their pursuit to prove the therapeutic potential of this important technology. We were encouraged by the results of this technology from the first cohort of our TUCSON stroke study and believe that SonoLysis has the potential to treat several other vascular disorders beyond ischemic stroke including peripheral artery disease, deep vein thrombosis and other life threatening indications. Although sales of our urokinase inventory served a valuable purpose in helping cash-flow the business since the time we acquired it from Abbott, the $17 million in proceeds generated through the divestiture of this asset will enable the company to focus on our core competency and work towards generating future value for our shareholders."

ABOUT SONOLYSIS

ImaRx's SonoLysis program involves the administration of its proprietary MRX-801 microbubbles and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The sub-micron size of MRX-801 microbubbles may allow them to penetrate a blood clot, so that when ultrasound is applied their expansion and contraction, or cavitation, can break the clot into very small particles. This technology was most recently evaluated in a Phase I/II clinical trial in combination with tPA in patients suffering from acute ischemic stroke.

ABOUT UROKINASE

Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The product has been commercialized for more than 20 years and has been administered to greater than four million patients. In 2006, ImaRx acquired urokinase and all related assets, including an approximate four-year supply of inventory, cell lines and manufacturing rights to the drug. Since October 2006, ImaRx has been selling its urokinase inventory in the U.S. market where it is estimated to be listed on pharmacy formularies at approximately 700 acute care hospitals and has generated $14.2 million in net proceeds through the fourth quarter of 2007.

COTTON & WESTERN MINING (OTC: CWRM)
"Up 50.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/CWRM.php

Cotton & Western Mining, Inc. (the “Corporation”), a pubic corporation traded under the symbol CWRM, was founded in early 2005 as a Nevada Corporation by Robert L. Cotton, with a specific plan and goal in mind; that being, to operate a low cost and high profit junior “Iron Mineral Mining” company. Iron ore mining can be a simple low-tech process or a very expensive and sophisticated undertaking.

CWRM News:

May 7 - Cotton & Western Mining, Inc. Nears Contract Completion for Domestic Mill Scale Project

Cotton & Western Mining, Inc. (OTC: CWRM) announced that the company is near completion of the sales contract and the shipping arrangements of Mill Scale from the Port of New Orleans to China. Due to recent surges in bulk cargo shipping charges, the cargo will be shipped in containers each holding 25 metric tons. Each shipment will be 400 containers totaling 10,000 metric tons.

Financing for the project is being undertaken by the LC Xchange, Inc. Houston, Texas U.S.A.

The CWRM Board of Directors approved this project to produce financial activity for the company during the pending permit process for the company's Baja Pacific Mining Project; which has been delayed until the third quarter of year 2008.

WHAT IS MILL SCALE?

Mill Scale consists primarily of magnetite, Fe3O4, of characteristic blue-gray "steely" color. An extremely thin outer film of hematite, Fe2O3, is invisible to the naked eye. The inner portion of the magnetite contains fine metal grains and sometimes, residual black FeO (see below), which contribute to the roughness of de-scaled metal. Mill Scale is found on all hot-rolled steel products unless processed in a protective atmosphere.

At hot rolling temperatures, an inner layer of wüstite, FeO, exists between the steel and magnetite. At elevated temperatures, FeO constitutes about 85% of the scale thickness, Fe3O4 about 10 to 15% and Fe2O3 about 0.5 to 2%. During slow cooling [below 1040 F] of hot-rolled coils of hot-rolled strip [and heavy shapes], most of the FeO is transformed to Fe and Fe3O4, and the latter oxide is predominant after cooling.

LUDWIG ENTERPRISES (OTC: LUDW)
"Up 60.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/LUDW.php

Ludwig Enterprises, Inc., (LUDW), is a Nevada based technology company with regional offices in Miami, Florida. LUDW has acquired various licenses and rights for revolutionary new methods of radio broadcasting. This technology attaches fifty new digital broadcast channels to an existing broadcast signal. This technology will allow Ludwig Enterprises to contractually acquire the right to utilize currently issued broadcast station spectrum with minimal regulatory requirements. The company intends to deploy this technology into the fifty largest US demographic markets. Taking advantage of a current void in the media market, Ludwig will target the rapidly emerging and underserved or un-served foreign language market. Programming will consist of twenty-four hour a day programs in such languages as Chinese, Pakistani, Russian, Hebrew and many others. Additionally there will be a limited number of specialty channels focusing on twenty-four hour a day old time radio programs, readings of local and national news papers (without commentary), specialty music channels including jazz and music forms not played on conventional stations, and educational programming. It is estimated that this initial target market is currently over 100 million people in the US. Additional information about Ludwig Enterprises, Inc. as well as corporate structure and stock capitalization can be viewed on the Company's Web site at www.ludwigent.com. Capitalization and filing information may also be viewed at www.pinksheets.com.

LUDW News:

May 6 - Ludwig Enterprises, Inc. Announces Selection of F.C.C. Attorneys

Ludwig Enterprises, Inc. (OTC: LUDW) Board of Directors announces selection of F.C.C. Attorneys, Womble Carlyle Sandridge & Rice, PLLC.

Ludwig's legal team will be headed by Womble Carlyle attorney Gregg Skall, a senior member of the Communications Bar. Mr. Skall has over 35 years experience in telecommunications legal issues and is a former Chief Counsel of the National Telecommunications and Information Administration.

Mr. Skall said that Ludwig's technology and business plan offer radio broadcasters exciting new opportunities for nontraditional revenue and program diversification and he is grateful that Womble Carlyle will be a part of the Ludwig team.

Mr. Skall will work directly with Patrick Greenish, Esq. president of Ludwig on legal matters relating to Ludwig's new Digital Broadcasting technology. The revolutionary new digital platform is planned to allow transmission of fifty (50) simultaneous channels of ethnic and alternative media broadcasting. The under-serviced or unserved foreign speaking market will have a medium to hear programs in their native languages. Content will include news from their homeland as well as content about activities in their local U.S. communities. Currently the US has about 30+ million foreign- born citizens or residents. Many in this group are middle or upper income producers. Many advertisers desire access to this group but have limited means to promote their products in a cost effective manner. Ludwig will link advertisers supply to targeted communities demand.

ABOUT WOMBLE CARLYLE

Womble Carlyle is a full-service business law firm, which ranks among AmLaw's 100 leading firms in the country. The firm is a recipient of the Thurgood Marshall College Fund Corporate Leadership Award, making Womble Carlyle the first law firm ever to receive the highest honor given to a business organization in recognition of its support of the Fund and its 45 member educational institutions.

Founded in 1876, Womble Carlyle operates in six states and the District of Columbia with nearly 550 attorneys in eleven offices located in Atlanta, GA; Greenville, SC; Charlotte, Greensboro, Raleigh, Research Triangle Park, and Winston-Salem, NC; Washington, DC; Tysons Corner, VA; Wilmington, DE; and Baltimore, MD. Womble Carlyle is located in the Southeast and mid-Atlantic regions, and serves clients nationally and globally.

Womble Carlyle's communications practice has a fifty-year tradition of assisting mass media and telecommunications businesses through their regulatory issues in Washington and their business issues in nearly every state in the country.

COATES INTERNATIONAL LIMITED (OTCBB: COTE)
"Up 60.94% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/COTE.php

Coates International, Ltd. develops Coates spherical rotary valve system (CSRV System) for use in piston-driven internal combustion engines. CSRV System is designed to replace the intake and exhaust conventional poppet valves used in piston-driven stationary, automotive, motorcycle, and marine engines. The company holds license to manufacture, sell, and grant sublicenses for its products in North America, Central America, and South America. Coates International was founded in 1987 and is based in Wall Township, New Jersey.

COTE News:

May 7 - Coates International, Ltd. Announces $1.1 Billion Equipment Financing Commitment Obtained by Well to Wire Energy, Inc.

Coates International, Ltd. (OTCBB: COTE) (the "Company" or "Coates") announced that Well to Wire Energy, Inc. ("WWE"), a Canada-based company that services the oil and gas industry throughout Canada and America, has secured a $1.1 Billion equipment lease finance commitment from Canada West Corporate Finance, Inc., which is to be utilized for its Coates CSRV engine generator purchases over the next five years pursuant to its licensing agreement with Coates. The five-year WWE business plan on which this commitment was based provides for the purchase of approximately 7,400 Engine Generators at a price per unit of $150,000. The parties are in the process of finalizing a definitive financing agreement.

WWE is continuing its efforts to raise new equity capital in order to fund a Release Payment due under an Escrow Agreement with the Company which represents payments currently due pursuant to the Canadian Research and Development and Licensing Agreements and the recently executed United States Licensing Agreement. WWE has made additional payments in April and May 2008, bringing the total amount of non-fundable deposits received by the Company to approximately $2,025,000. The remaining balance of the Release Payment at this time is approximately $8,975,000. WWE may only draw down on the $1.1 Billion financing commitment for the acquisition of Coates CSRV Electric Power Natural Gas Generators.

Barry C. Kaye, CFO stated that this marks an extremely positive development for Coates and because WWE will be backed by a secure financial resource, he considers this a critical step in reducing the business risk related to collection of the proceeds from CSRV Engine Generator sales.

George J. Coates added that this represents significant progress in moving the Company towards its goal of being able to promptly commence production of Coates CSRV Engine Generators for WWE upon receipt of a sufficient portion of the Release Payment due from WWE.

The Company is continuing active discussions with other third parties in connection with additional commercially viable applications of the CSRV technology.

About Coates International, Ltd.: Coates has completed development of its patented spherical rotary valve CSRV Industrial Internal Combustion Engine developed over a period of more than 6 years and other CSRV applications over 10 years. The underlying CSRV technology was invented by George J. Coates and his son Gregory. The CSRV system is adaptable to combustion engines of many types. This technology is currently adapted to a number of practical applications including industrial generators powered by engines incorporating the CSRV technology and designed to run on flare-off gas from oil wells, landfill gas and raw natural gas. The company is actively engaged in planning for production and rollout of these engines.

BIONIC PRODUCTS INCORPORATED (OTC: BNPD)
"Up 120.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/BNPD.php

Bionic Tonic and Lady Pink are refreshing energy drinks providing increased energy without the calories and sugar. Our products contain the finest ingredients available to assist metabolic levels and burn calories. Bionic's distribution is being targeted to wellness centers, trendy retail outlets and night clubs. The power and energy drink business is one of the fastest growing sectors in the entire beverage industry. Bionic Products, Inc. is a Nevada Corporation formed for the purpose of discovering, developing and marketing breakthrough energy drinks and bottled water that will enhance the health and wellness of consumers. The company's common stock is traded on the OTC under the symbol "BNPD." For more information or a copy of Bionic's research report, visit www.ladypinkdrink.com.

BNPD News:

January 3 - Bionic Products, Inc. Announced Positive Feedback From New Year's Promotional Campaign

Bionic Products, Inc. (OTC: BNPD) announced the immense success of its initial promotional blast for Bionic Tonic and Lady Pink in the greater Tampa area.

Bionic Products conducted a soft launch to introduce Lady Pink and Bionic Products to the Tampa market. The campaign targeted nightlife, restaurants, and convenience stores. The promotional blitz included sampling of the products, professionally designed brochures, targeted business cards, product-specific flyers and signage on key professional private transportation vehicles such as limousines. The success is attributed to the strong interest expressed from local business owners who are constantly seeking new and exciting products to offer their customers.

Mr. Pulver, VP/Director of Bionic Products, said that, "This is the first of many promotional campaigns we intend to do this year. We have teamed up with a national events company, Club Scene (Club Scene Network, Inc.) and a vodka company to start aggressive campaigns throughout southern Florida." Club Scene recently launched www.ClubSceneFashion.com, which targets fashion for nightlife and Lady Pink is one of the main sponsors for their events.

The company has formed an alliance with an investor relations group to help grow our shareholder base while keeping the existing shareholders and the public updated on the advancement of our business model. Production is scheduled to start soon which will lead to immediate revenues for the Company.